At face value, Fortis Therapeutics Inc. might seem like just another pretty preclinical immuno-oncology (I-O) project. But Jay Lichter, president and CEO of Fortis and COI Pharmaceuticals Inc. – which is housing the startup – and managing director of Avalon Ventures called the San Diego-based company's platform "absolutely the most advanced program we've ever seen, with the most high-quality data."